Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lipocine has received a $2m development milestone payment from Abbott under the terms of its licensing agreement to develop and commercialise an oral testosterone product for hypogonadism, also known as low testosterone (low T).
Subscribe to our email newsletter
As per the terms of the agreement, Abbott is expected to make milestone payments and pay royalties to Lipocine based upon product sales. Abbott is responsible for all development expenses associated with this program, which is currently in Phase I development.
Mahesh Patel, president and CEO of Lipocine, said: “We are pleased with the progress of the joint development program and look forward to a productive relationship with Abbott. An oral product has the potential to be the next innovation in the management of low testosterone.
“Through improved patient compliance an oral testosterone product is expected to expand options for doctors and patients in management of low testosterone.”
Lipocine licensed a patented investigational oral testosterone product to Solvay Pharmaceuticals (now part of Abbott, the global health care company) in May 2009.
Lipocine is a pharmaceutical company leveraging its proprietary drug delivery technologies to commercialize pharmaceutical products.